BioRestorative Therapies Inc (BRTX) Quote

BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment

BRTX under $2

I’m very happy to see Auct-ass going down.

BRTX under $2

$BRTX. so sad
BIORESTORATIVE THERAPIES INC
$1.57-1.88 (-54.49%)

BRTX new 52 week low

That didn’t age well. Just got dumped on with new warrants and more dilution!! It’s a scam like the others u mentioned.

Aaaaand down she goes. Lance is scum of the earth and this is a scam.

Back down again

sure has - $BRTX

It's been a long time coming.

Nice to see the team pulling this out of the fire.

spike to 4.50,she can really fly, "FLY MY PRETTY!!" 60% move from close is beautiful

Out at 4.34

$BRTX BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease

BioRestorative Therapies, Inc. (“BioRestorative”, “$BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced the public availability of a poster, presented yesterday at the Orthopaedic Research Society (ORS) 2024 Annual Meeting, which describes preliminary 26 and 52 week blinded data from the ongoing Phase 2 clinical trial of the Company’s lead clinical candidate, BRTX-100, in subjects with chronic lumbar disc disease (“cLDD”).
The presented poster, titled “Autologous Stem Cell Therapy for Chronic Lumbar Disc Disease; Initial Phase 2 Clinical Safety and Feasibility Data of Intradiscal Injections of Hypoxic Cultured Mesenchymal Stem Cells” can be accessed on the Company’s website at www.biorestorative.com under “Scientific Publications” in the Product Candidate section. During a webcasted conference call scheduled for 8:30am EST today, BioRestorative management will be available to discuss data from the presentation as well as provide a clinical update.

Previous clinical studies have demonstrated that the harsh microenvironment of the disc could impact cell dose viability and result in a non-efficacious or the worsening of clinical outcomes. Although this is blinded and early clinical data, it is important to note that the Visual Analog Scale, Oswestry Disability Index, Roland Morris Disability Questionnaire, and Functional Rating Index collected at weeks 26 and 52 post-injection demonstrated a positive trend compared to baseline. In addition to safety outcomes, changes to these pain and function scales compared to baseline are used by the U.S. Food and Drug Administration (FDA) to determine whether the trial will be allowed to proceed and ultimately gain Biologics License Application (BLA) approval.

“We are thrilled with the progress of our ongoing clinical development programs. With regard to the Phase 2 study investigating the use of BRTX-100 in the treatment of cLDD, we are strongly encouraged by the preliminary data presented at ORS 2024. The preliminary clinical data shows meaningful signals in patients enrolled in the study and, importantly, no notable safety signals,” said Lance Alstodt, Chief Executive Officer of BioRestorative.

Liking PM.

6month high Fri.,and look at the green on the candles on here,tremendous buying going on.

New 2 day high,vol increase,I am excited

They seem excited;)
https://www.biorestorative.com/press-releases/

Conference call/presentation on Mon at 8:30am est,last time stock was halted until presentation was over.

Looking good for Monday

debt only 198K (yahoo finance info)

12M cash,,no offerings/no warrents endlessly dumping like most other tickers that trade 10m-30m shares and never move up,BRTX went up 25% on 500k

Roth mkm analyst's target $15.00

demand building,40K@ 2.60(the moving ave support)

10Xs ave vol,165Xs relative buying vol!!!!,exceeded yesterdays total vol already today

watch for bounce off ma's @ 2.60

conf. call monday,prelimb data/current plans,patent approval was dec.12th,poked thru the sma200 today @2.88(blue sky ma resistance above that,last time it poked thru it ran up 100%)

BioRestorative Therapies Receives a Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its Obesity Program
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the United States Patent and Trademark Office has issued a notice of allowance for a patent application related to the Company’s metabolic ThermoStem® program. The notice of allowance was issued on October 26, 2023. The application is scheduled to issue as U.S. Patent No. 11,851,682 on December 26, 2023.
This will be the fourth U.S. patent granted under this particular patent family. Claims granted under the new patent cover methods of using differentiated human brown fat adipocytes as a platform to screen and identify compounds that can activate and regulate metabolic activity. These compounds, if discovered to provide metabolic benefits, can then be further developed into drugs targeting weight loss. Therapeutic benefits of using activated brown adipose have been demonstrated in various models and may provide a valuable therapeutic tool for treating a range of metabolic disorders. For example, studies have shown that GLP-based therapeutics interact with brown adipose tissue.

“This notice of allowance is an important milestone as it provides us with tools that can be used as a platform to screen large libraries of compounds targeting metabolic disorders such as obesity,” said Lance Alstodt, the Company’s CEO. “The prevalence of developmental pipelines targeting obesity has increased substantially over the past year. As a result there is a need for more advanced targeted and precise tools and methods for identifying such compounds. This notice of allowance will afford us the protections necessary to allocate resources to develop these extremely valuable tools.”

I have way too much money in this stock. Maybe I will see profits in a year or two. Sheesh!!!!

Everything is going great at the company level.... why isn't the stock appreciating?

Very disappointing performance

BRTX under $2

Boom time….

possible bottom at $1.45

BioRestorative Therapies Announces Activation of Northwell Health in the Companys Phase 2 Clinical Trial Targeting Chronic Lumbar Disc Disease
8:30 AM ET 9/8/23 | GlobeNewswire

BioRestorative Therapies Announces Activation of Northwell Health in the Company's Phase 2 Clinical Trial Targeting Chronic Lumbar Disc Disease

--Site activation allows for patients in the State of New York to participate in the BRTX-100 trial--

--15 Clinical Sites Identified, 12 of the 15 Activated and Recruiting Subjects

MELVILLE, N.Y., Sept. 08, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . ("BioRestorative", "BRTX" or the "Company") (NASDAQ: BRTX ) , a clinical stage company focused on stem cell-based therapies, today announced that Northwell Health, New York State's largest health care provider, has been activated and can now start recruitment in the State of New York for BioRestorative's ongoing Phase 2 clinical trial targeting chronic lumbar disc disease ("cLDD"). BioRestorative and Northwell Health entered into a clinical trial agreement in May with regard to the Phase 2 trial. Much effort and collaboration have taken place and, now that site specific training is complete, the site can initiate patient recruitment and enrollment.

BRTX-100, the Company's lead clinical candidate, is a novel cell-based therapeutic engineered to target areas of the body that have little blood flow and limited oxygen supply. It is currently being evaluated in connection with the Company's ongoing Phase 2 clinical trial targeting cLDD. The trial is prospective, randomized, double-blinded and controlled. The trial will evaluate the safety and preliminary efficacy of a single dose of BRTX-100, with 40 million cells injected into the lumbar disc that is causing pain. A total of up to 99 eligible patients will be randomized at up to 15 clinical sites in the United States to receive either the investigational drug (BRTX-100) or control in a 2:1 fashion. BioRestorative recently completed its safety run-in phase of the Phase 2 trial and is now openly enrolling patients across all its clinical sites located throughout the United States.

"I'm pleased to report that, after several months of a deliberate and thoughtful collaboration with Northwell Health, the largest healthcare provider and employer in New York State, we have reached the point of initiating the patient enrollment process. Given the size of Northwell Health and its relative proximity to our facilities in Melville, New York, we look forward to significant benefits from working with Northwell Health in connection with our Phase 2 clinical trial. We hope that our partnership will result in a highly efficient recruitment / enrollment process among other significant benefits," stated Lance Alstodt, Chief Executive Officer of BioRestorative.

Dr. Sohrab Virk of Northwell Health stated, "Everyone at Northwell is laser focused on improving clinical outcomes related to the spine. The technology of BRTX-100 represents a new hope for improving pain/functionality for our patients dealing with discogenic pain. We are eager to begin our investigation and hope to bring the extensive clinical volume and outstanding physician talent at Northwell to help with this trial."

Dr. Virk is an orthopedic surgeon who specializes in the treatment of spine-related issues, specifically using minimally invasive surgical techniques and motion sparing technology. He is also an assistant professor of Orthopedic Surgery at the Donald and Barbara Zucker School of Medicine at Hofstra University.

Northwell Health is New York State's largest health care provider and private employer, with 21 hospitals, 850 outpatient facilities and more than 12,000 affiliated physicians. The partnership will enable Northwell Health to begin active recruitment and enrollment in BioRestorative's clinical trial targeting patients suffering from chronic lumbar disc disease.

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:

-- Disc/Spine Program (brtxDISC(TM) ): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient's bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient's damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have commenced a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from chronic lumbar disc disease.

-- Metabolic Program (ThermoStem(R) ): We are developing a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue ("BAT"). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.

At this point it’s hard to deny that this is and always has been, nothing more than a share selling scam.

$BRTX they got a pay raise and the stock takes a dump ...lol

JUST CHECKING IN. THANKS FOR THE CAR IN 2020. WHAT A RUN WE HAD WITH THAT COURT NEWS. I THINK IMA ADD SOME AROUND HERE FOR SHITS AND GIGGLES AND SELL AT 4. WE CALL DAT A DUB DUB.

Never invest in Biotechs.
Lesson learned long ago.

Form 424B5 - Prospectus [Rule 424(b)(5)]
August 23 2023 - 05:03PM
Edgar (US Regulatory)
Alert
Print
Share On Facebook


Filed Pursuant to Rule 424(b)(5)
Registration No. 333-269631

SUPPLEMENT NO. 3 TO PROSPECTUS SUPPLEMENT DATED APRIL 14, 2023
(To Prospectus dated February 14, 2023)
$6,109,000



BioRestorative Therapies, Inc.
Common Stock
_________________________

This Supplement No. 3, or this Supplement, modifies and amends, only to the extent indicated herein, certain information contained in our prospectus supplement, dated April 14, 2023, or the Original Supplement, filed by us with the Securities and Exchange Commission, or the SEC, on April 14, 2023, Supplement No. 1 to the Original Supplement, dated May 15, 2023, or the First Supplement, filed by us with the SEC on May 15, 2023 and Supplement No. 2 to the Original Supplement, dated July 11, 2023, or the Second Supplement, filed by us with the SEC on July 11, 2023, and relating to the offer and sale of shares of our common stock, par value $0.0001 per share, from time to time pursuant to a Capital on Demand™ Sales Agreement, or the Sales Agreement, with JonesTrading Institutional Services LLC, or the Agent. The Original Supplement supplemented our prospectus, dated February 14, 2023 (together with the Original Supplement, the Original Prospectus). The First Supplement supplemented the Original Prospectus. The Second Supplement supplemented the Original Prospectus and the First Supplement. This Supplement, the Second Supplement, the First Supplement and the Original Prospectus form part of our Registration Statement on Form S-3, dated February 14, 2023 (Registration No. 333- 269631), or the Registration Statement.

This Supplement is being filed to amend certain information contained in the Original Prospectus, the First Supplement and the Second Supplement to update our disclosure therein regarding the dollar amount of shares which we may sell in any 12 calendar month period pursuant to the Registration Statement and the Sales Agreement and in accordance with General Instruction I.B.6 of Form S-3.

This Supplement should be read in conjunction with the Second Supplement, the First Supplement, the Original Prospectus and the Registration Statement, and is qualified by reference to the Second Supplement, the First Supplement, the Original Prospectus and the Registration Statement, except to the extent that the information presented herein supersedes the information contained in the Second Supplement, the First Supplement, the Original Prospectus or the Registration Statement. This Supplement is not complete without, and may only be delivered or used in connection with, the Second Supplement, the First Supplement and the Original Prospectus, including any amendments or supplements thereto. If there is any inconsistency between the information in the Second Supplement, the First Supplement, the Original Prospectus and this Supplement, you should rely on the information in this Supplement.

Since the date of the Second Supplement, our public float has increased such that we may sell additional amounts of common stock under the Sales Agreement and the Registration Statement. Accordingly, we are filing this Supplement to amend the Original Prospectus, the First Supplement and the Second Supplement to reflect such increase in our public float and such ability to sell additional common stock under the Sales Agreement and the Registration Statement.

The aggregate market value of our outstanding common stock held by non-affiliates, or the public float, as of the date hereof pursuant to General Instruction I.B.6 of Form S-3 is $24,554,149, which was calculated based on 3,783,382 shares of our outstanding common stock held by non-affiliates and at a price of $6.49 per share, the closing price of our common stock on June 26, 2023 (which was the highest closing sale price of our common stock on the Nasdaq Capital Market within the 60 days prior to the date hereof).

Accordingly, based on our public float of $24,554,149 as of the date hereof, and in accordance with General Instruction I.B.6 of Form S-3, we may sell our securities in a public primary offering with a value not to exceed $8,184,716 (which is less than one-third of our public float) in any 12 calendar month period. We have sold $2,612,243 of securities pursuant to General Instruction I.B.6 of Form S-3 during the 12 calendar months prior to and including the date of this Supplement, including $536,593 of securities in accordance with the Sales Agreement and $2,075,650 of securities pursuant to a separate public primary offering. Therefore, this Supplement hereby amends the Original Prospectus, the First Supplement and the Second Supplement to reflect that we may offer and sell shares of our common stock having an aggregate offering price of up to $6,109,000 in any 12 calendar month period from time to time through or to the Agent in accordance with the Sales Agreement (including the $536,593 of our securities that we have sold to date in accordance with the Sales Agreement). Following the filing of this Supplement and the increase in the amount of shares as described above, as of the date of this Supplement, we will have approximately $5,572,473 of availability for future sales of securities in accordance with the Sales Agreement. If our public float further increases such that we may offer and sell more than $8,184,716 of our securities under General Instruction I.B.6 of Form S-3, we will file another prospectus supplement prior to making sales in excess of such amount.

Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell our securities in a public primary offering with a value exceeding one-third of our public float in any 12 calendar month period so long as our public float remains below $75 million.

Our common stock is listed on the Nasdaq Capital Market under the symbol “BRTX.” The last reported sales price of our shares of common stock on August 22, 2023 was $2.54 per share.


Investing in our common stock involves risks. See the section entitled “Risk Factors” beginning on page S-7 of the Original Supplement and in the documents we incorporate by reference into the Original Prospectus.


Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this Supplement or the accompanying Original Prospectus. Any representation to the contrary is a criminal offense.
JonesTrading
The date of this prospectus supplement is August 23, 2023
BioRestorative Therapies (NASDAQ:BRTX)
Historical Stock Chart
From Jul 2023 to Aug 2023 Click Here for more BioRestorative Therapies Charts. BioRestorative Therapies (NASDAQ:BRTX)
Historical Stock Chart
From Aug 2022 to Aug 2023 Click Here for more BioRestorative Therapies Charts.


https://ih.advfn.com/stock-market/NASDAQ/biorestorative-therapies-BRTX/stock-news/91884835/form-424b5-prospectus-rule-424b5

$BRTX man they get their $$$ what a fleecing sure would be nice to get the share price up some if they want that kind of $$

https://ih.advfn.com/stock-market/NASDAQ/biorestorative-therapies-BRTX/stock-news/91740031/form-def-14a-other-definitive-proxy-statements

Stay far away from this. Lance will take your money and soul.

BRTX BioRestorative Therapies Has Been Granted A License By The New York State Department Of Health To Operate As A Tissue Bank; The License Enables BioRestorative To Process Mesenchymal Stem Cells Obtained From Autologous Donors

$BRTX - Up 12% Pre-Market/ Current Price $3.36
Receives Landmark License From New York State

New offering of stock...

https://ih.advfn.com/p.php?pid=nmona&article=91546271

$BRTX $BRTX's Drug Candidate BRTX-100 🚀 Excels In #Safety Test, Advances To Phase 2 And Expands Pipeline@BioRestorative Therapies Inc. has received a unanimous recommendation to proceed in its Phase 2 clinical trial for chronic lumbar disc disease

👉https://t.co/aapnoETzXe#ad pic.twitter.com/9DJgKkoxJe— Benzinga (@Benzinga) July 12, 2023

$BRTX
https://www.benzinga.com/general/biotech/23/07/33129744/biorestorative-therapies-drug-candidate-brtx-100-passes-safety-test-with-flying-colors-moves-ahea#

https://t.co/ouycbwjrdo @Benzinga— BioRestorative Therapies, Inc. (@BioRestorative) July 6, 2023

Between the two, I'd vote Auctus, given the collapse of the credit markets. On the flip side, if its BRTX, they will feel some pain from their shareholders.

That was a pretty quick dump... wonder if it's the company or Auctus selling some shares?

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171887384

Okay wtf happened now ?